Search Orphan Drug Designations and Approvals
-
Generic Name: | sirolimus | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Rapamune | ||||||||||||||||
Date Designated: | 10/31/2012 | ||||||||||||||||
Orphan Designation: | Treatment of lymphangioleiomyomatosis | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Pfizer, Inc. 500 Arcola Road Collegeville, Pennsylvania 19426 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | sirolimus |
---|---|---|
Trade Name: | Rapamune | |
Marketing Approval Date: | 05/28/2015 | |
Approved Labeled Indication: | Treatment of lymphangioleiomyomatosis (LAM) | |
Exclusivity End Date: | 05/28/2022 | |
Exclusivity Protected Indication* : | Treatment of lymphangioleiomyomatosis (LAM) | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-